EICHORPublic-registry site landscape for NCT03018067, “A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia”, a Hyperkalemia study sponsored by Ardelyx. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03018067 (registry record) |
| Study title | A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia |
| Official title | A Single-Blind, Placebo-Controlled Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia |
| Sponsor | Ardelyx |
| Condition(s) | Hyperkalemia |
| Phase | PHASE2 |
| Listed sites | 1 |
| Intervention(s) | RDX227675, Placebo |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03018067.
Eichor generates a preliminary site-risk snapshot for NCT03018067 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
